Solasia Pharma (Solasia) has completed phase I clinical trial for SP-01 (extended release transdermal granisetron patch, brand name: Sancuso ) in Japanese volunteers.
Sancuso is the first and only commercialised extended release granisetron transdermal product. Sancuso was approved for the prevention of chemotherapy-induced nausea and vomiting and launched in the US in 2008.
The company has also announced that a US patent for Sancuso was granted on October 27, 2009 to ProStrakan Group, which developed and own the worldwide rights to Sancuso. The patent relates to a transdermal patch containing granisetron.
Steve Engen, president of Solasia, said: “We are very pleased that Prostrakan has obtained the grant of the US patent for Sancuso. This follows patent grants in the EU in 2007 and Japan in 2008, and reaffirms our confidence in the strength of the IP relative to other transdermal granisetron formulations including all such products currently in clinical development in Japan.”